Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 11-20 of 104 for alzheimer's

Edit search filters
  1. An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

    Jacksonville, FL

  2. An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

    Jacksonville, FL

  3. A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

    Jacksonville, FL

  4. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

    Rochester, MN

  5. A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

    Jacksonville, FL

  6. A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer's Disease

    Scottsdale/Phoenix, AZ

  7. A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

  8. A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

  9. A Study to Evaluate the Safety and Effectiveness of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

    Scottsdale/Phoenix, AZ

  10. Effects of Aging and Aerobic Exercise Training on Brain Glucose Metabolism

    Rochester, MN

.

Mayo Clinic Footer